Philippe Camus, M.D.
Dijon, France
XXXVI - Autoimmune syndromes - Systemic reactions or conditions
Last update 17/06/2026
(ANA : Antinuclear antibodies). Subclinical organ damage or dysfuction should be investigated. See also under Xd and Xe
XII. Pericardial involvement
XII.g Pleural/pericardial effusion, ANA positive (DI lupus)
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XIV. Pleural involvement
XIV.h Pleural thickening - Fibrothorax
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.j Organizing pneumonia (OP/BOOP) pattern (an area or areas of consolidation on imaging)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.d Subclinical ANA positivity
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XX. Vasculitis
XX.d Vasculitis, pulmonary (w/wo AH), extrathoracic, or systemic: ANCA-positive
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.j Organizing pneumonia (OP/BOOP) pattern (an area or areas of consolidation on imaging)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.b Lupus - Lupus syndrome
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.d Subclinical ANA positivity
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XI. Pulmonary vasculopathies
XI.f Worsening of preexisting PHTn
XII. Pericardial involvement
XII.g Pleural/pericardial effusion, ANA positive (DI lupus)
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XIV. Pleural involvement
XIV.h Pleural thickening - Fibrothorax
XXII. Acute respiratory/cardiorespiratory failure
XXII.e Respiratory failure from ventilatory depression (of neuromuscular cause or causes)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.e Relapsing or migrating pneumonitis/pneumonia (see also Id)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.h Pulmonary fibrosis (may improve but partly following drug discontinuation)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.j Organizing pneumonia (OP/BOOP) pattern (an area or areas of consolidation on imaging)
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
XXIX. Small airway involvement
XXIX.c Severe or catastrophic bronchospasm or asthma attack (can be fatal)
XXIX. Small airway involvement
XXIX.h Exacerbation or deterioration of preexisting asthma
XXIX. Small airway involvement
XXIX.i Exacerbation or deterioration of preexisting COPD
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.b Lupus - Lupus syndrome
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.d Subclinical ANA positivity
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.l Refractoriness to epineprine in case of anaphylaxis
XXXVIII. Miscellaneous - Varia
XXXVIII.d Death following exposure or poisoning
